Well, frontotemporal dementia doesn’t get as much attention as Alzheimer’s disease or Lewy body disease, but it is a major cause of dementia and can strike people in middle age. So it’s most commonly affecting people in their 50s or early 60s, one of the more common young-onset neurodegenerative dementias. And I’m very proud of my colleagues, Bill Seeley and Gil Rabinovitch, who are receiving the Potamkin Prize at this 2025 American Academy of Neurology meeting...
Well, frontotemporal dementia doesn’t get as much attention as Alzheimer’s disease or Lewy body disease, but it is a major cause of dementia and can strike people in middle age. So it’s most commonly affecting people in their 50s or early 60s, one of the more common young-onset neurodegenerative dementias. And I’m very proud of my colleagues, Bill Seeley and Gil Rabinovitch, who are receiving the Potamkin Prize at this 2025 American Academy of Neurology meeting. They’ve both dedicated themselves to frontotemporal dementia and young-onset Alzheimer’s disease. Dr Seeley focusing more on FTD, Dr Rabinovitch focusing more on young-onset and atypical forms of Alzheimer’s disease. So we’ll hear their lectures at the meeting. And there’s also a tremendous amount of excitement about new biomarkers and imaging methods to measure the progression or type of frontotemporal dementia that hopefully will be in a position in the next few years to be more similar to Alzheimer’s disease and some of the emerging biomarkers in Lewy body disease where we can have a more precise diagnosis of the underlying form of FTD. Because it’s difficult to know right now whether it’s tau-related or TDP43-related and hopefully in the next few years we’ll see more imaging or fluid biomarkers that can make that distinction more obvious.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
